Bluebird bio Inc

NASDAQ:BLUE  
6.34
+0.64 (+11.23%)
Products

Bluebird Bio Announces U.S. Commercial Infrastructure To Enable Patient Access To Zynteglo

Published: 08/17/2022 18:38 GMT
Bluebird bio Inc (BLUE) - Bluebird Bio Announces U.S. Commercial Infrastructure to Enable Patient Access to Zynteglo®, the First and Only FDA-approved Gene Therapy for People With Beta-thalassemia Who Require Regular Red Blood Cell Transfusions.
Bluebird Bio - Zynteglo Will Be Available Through a Network of Qualified Treatment Centers With Experience Delivering Novel Cell and Gene Therapies.
Bluebird Bio Inc - Are Engaging With State Medicaid Agencies Representing Approximately 80% of Publicly Insured Thalassemia Patients.